Last reviewed · How we verify
Sensipar after Post Transplant — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Sensipar after Post Transplant (Sensipar after Post Transplant) — Amgen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sensipar after Post Transplant TARGET | Sensipar after Post Transplant | Amgen | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sensipar after Post Transplant CI watch — RSS
- Sensipar after Post Transplant CI watch — Atom
- Sensipar after Post Transplant CI watch — JSON
- Sensipar after Post Transplant alone — RSS
Cite this brief
Drug Landscape (2026). Sensipar after Post Transplant — Competitive Intelligence Brief. https://druglandscape.com/ci/sensipar-after-post-transplant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab